190 related articles for article (PubMed ID: 36083778)
1. Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis.
Xu H; Liu Z; Weng S; Dang Q; Ge X; Zhang Y; Ren Y; Xing Z; Chen S; Zhou Y; Ren J; Han X
Mol Oncol; 2022 Dec; 16(22):4023-4042. PubMed ID: 36083778
[TBL] [Abstract][Full Text] [Related]
2. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
Liu Z; Guo C; Dang Q; Wang L; Liu L; Weng S; Xu H; Lu T; Sun Z; Han X
EBioMedicine; 2022 Jan; 75():103750. PubMed ID: 34922323
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer.
Wang L; Liu Z; Liang R; Wang W; Zhu R; Li J; Xing Z; Weng S; Han X; Sun YL
Elife; 2022 Oct; 11():. PubMed ID: 36282174
[TBL] [Abstract][Full Text] [Related]
5. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
6. N6-methylandenosine-related immune genes correlate with prognosis and immune landscapes in gastric cancer.
Huang Y; Zou Y; Tian Y; Yang Z; Hou Z; Li P; Liu F; Ling J; Wen Y
Front Oncol; 2022; 12():1009881. PubMed ID: 36523987
[TBL] [Abstract][Full Text] [Related]
7. Identification of an Individualized Prognostic Signature Based on the RWSR Model in Early-Stage Bladder Carcinoma.
Liu L; Zhong X; Cui H; Zhang H; Wang L; Liu Y
Biomed Res Int; 2020; 2020():9186546. PubMed ID: 32596394
[TBL] [Abstract][Full Text] [Related]
8. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma.
Lin P; Wen DY; Chen L; Li X; Li SH; Yan HB; He RQ; Chen G; He Y; Yang H
Eur Radiol; 2020 Jan; 30(1):547-557. PubMed ID: 31396730
[TBL] [Abstract][Full Text] [Related]
9. Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?
Loeffler CML; Ortiz Bruechle N; Jung M; Seillier L; Rose M; Laleh NG; Knuechel R; Brinker TJ; Trautwein C; Gaisa NT; Kather JN
Eur Urol Focus; 2022 Mar; 8(2):472-479. PubMed ID: 33895087
[TBL] [Abstract][Full Text] [Related]
10. Unraveling neoantigen-associated genes in bladder cancer: An in-depth analysis employing 101 machine learning algorithms.
Lv F; Xiong Q; Qi M; Dai C; Zhang X; Cheng S
Environ Toxicol; 2024 May; 39(5):2528-2544. PubMed ID: 38189174
[TBL] [Abstract][Full Text] [Related]
11. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
15. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J
J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering.
Hu X; Wang Z; Wang Q; Chen K; Han Q; Bai S; Du J; Chen W
Biomed Pharmacother; 2021 Dec; 144():112222. PubMed ID: 34607103
[TBL] [Abstract][Full Text] [Related]
18. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
[TBL] [Abstract][Full Text] [Related]
20. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
